Levodopa in the treatment of Parkinson's disease.

Levodopa is at present the most effective treatment of Parkinson's disease. Its use in combination with a peripheral decarboxylase inhibitor prolongs the elevation of plasma levels and decreases the incidence of peripheral side effects. Severe psychiatric and neurologic side-effects may necessitate reduction or cessation of the drug.

[1]  K. Jellinger,et al.  Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. , 1973, Journal of the neurological sciences.

[2]  D. Calne.  Progress in the treatment of Parkinsonism , 1973 .

[3]  O. Hornykiewicz,et al.  The neurochemistry of Parkinson's disease: effect of L-dopa therapy. , 1975, The Journal of pharmacology and experimental therapeutics.

[4]  L. Lasagna,et al.  L-dopa treatment failure: explanation and correction. , 1970, British medical journal.

[5]  J. Bianchine.  [Drug therapy of parkinsonism]. , 1976, Tidsskrift for Den Norske Laegeforening.

[6]  F. Mcdowell,et al.  Second Canadian-American conference on Parkinson's Disease , 1974 .

[7]  M. Critchley.  Drug Treatment of Parkinsonism , 1958, The New Zealand medical journal.

[8]  R. Duvoisin,et al.  Drug therapy of parkinsonism. , 1972, The New England journal of medicine.